maus
maus with http://www.mdnewscast.net

maus

Medical Newscast

News for 18-Sep-25

Source: MedicineNet Diabetes General
FDA OKs High-Tech Diabetes Device to Help Replace Fingerstick Tests

Source: MedicineNet Diabetes General
Daily Can of Soda Boosts Odds for Prediabetes, Study Finds

Source: MedicineNet Diabetes General
glipizide and metformin (Metaglip has been discontinued in the US)

Source: MedicineNet High Blood Pressure General
Yoga Called Good Medicine for High Blood Pressure

Source: MedicineNet Diabetes General
Health Tip: Creating an Insulin Routine

Source: MedicineNet High Blood Pressure General
Stressed Childhood Might Raise Risk for High Blood Pressure Later

Source: MedicineNet High Blood Pressure General
High Blood Pressure Rates Have Doubled Worldwide Since 1975

Source: MedicineNet High Blood Pressure General
Normal Blood Pressure in Clinic May Mask Hypertension

Source: MedicineNet Diabetes General
Can Protein, Probiotics Help With Blood Sugar Control?

Source: MedicineNet High Blood Pressure General
Bonus From Your Blood Pressure Med: Fewer Fractures?

Search the Web
maus
gamewheel
virus defense
data centers
global
microsoft intellipoint
assigning
automouse
xfig
m s48a

The Best maus website

All the maus information you need to know about is right here. Presented and researched by http://www.mdnewscast.net. We've searched the information super highway far and wide to provide you with the best maus site on the internet today. The links below will assist you in your efforts to find the information that you are looking for about
maus.

maus

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

We consider ourselves experts in the field of maus, we have a great interest in the subject and have dedicated a great amount of our own time sourcing good solid maus information.

Once we had our database of maus web sites we sifted through it closely and came to the conclusion most of the entries were just rubbish. However we did find several which we are sure will provide you with exactly the maus info you are looking for and invite you to click one of the links below.

maus

Medical Newscast
For information about Medical Newscasts look no further. We have links to great resources regarding all forms of medical internet broadcasting.
Medical Newscast

Shopping online for maus offers lots of benefits that you won't find shopping in a maus store or catalogue. For example, the Internet is always open - seven days a week, 24 hours a day.

Many maus bargains can only be found online. Shopping on the Internet is no less safe than shopping in a store or by mail. Keep the following tips in mind to help ensure that your maus shopping experience is a safe one.

Drug Offers Hope to Cancer Patients

 by: ARA Content

(ARA) - A decade ago, research into angiogenesis-inhibiting compounds was still in a relative state of infancy. The principle itself was not new -- as far back as the early '70s, there was speculation that human cancer tumors could not grow beyond a few millimeters in diameter without obtaining their own blood supply. But opinion was still divided in the scientific community.

Angiogenesis itself is a natural and necessary physiological function, which refers to the process by which new blood vessels form and develop. In its pathological form, however, angiogenesis is also implicated in the progression of more than 20 different diseases, including cancer.

In order to grow, solid tumors need to be supplied by blood vessels that act as conduits for oxygen and nutrients. Once a vascular network has been generated around a tumor, cancerous cells can then invade the rest of the body, a process called metastasis. Angiogenesis inhibitors block the formation of new blood vessels, without which cancerous cells are starved and tumors cannot grow.

In recent years, the therapeutic potential of angiogenesis inhibitors has gained wide acceptance. Indeed, the scientific community now believes that more than 90 percent of all cancer cases are angiogenesis dependent. The industry spends nearly $4 billion annually in angiogenic research and more than 100 research organizations and companies are currently developing angiogenesis-blocking drugs.

Ęterna Laboratories Inc. is at the forefront of this effort. In fact, it is one of the very few biotechnology companies in the world with an angiogenesis-blocker in Phase lll clinical development. Its proprietary compound, Neovastat, is currently the subject of Phase III trials in lung and kidney cancer and a Phase ll trial in multiple myeloma, a form of blood cancer.

Neovastat possesses multiple mechanisms of action that counteract the angiogenic process. Among competing products, this makes it unique. It has also shown an excellent safety profile in clinical trials. Further advantages of Neovastat are that it is orally administered, which makes it convenient for patients who must receive treatment on a long-term basis, and it may be taken in association with standard therapies such as chemotherapy.

Angiogenesis blockers are not a cure for cancer. They are a form of treatment -- in the same way that insulin is a treatment for diabetes -- that should allow patients to lead a more normal life, without suffering from the often debilitating side-effects that some treatments can produce.

Ęterna's clinical trials strategy has targeted forms of cancer for which there is an urgent need for new therapies. Since 1996, Neovastat has been tested in more than 850 patients in North American and European countries. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer. For multiple myeloma, the second most common form of blood cancer, the drug is in Phase II trials with 125 patients in the United States, Canada and Europe. This trial should be completed in early 2003. For progressive renal cell carcinoma, the drug is in Phase III trials with 302 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a Phase III trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005.

Once the clinical trials are complete, health authorities in various countries can then assess these results and make decisions on approval.

About The Author

Courtesy of ARA Content, www.ARAcontent.com; e-mail: info@ARAcontent.com

EDITOR'S NOTE: For more information about current trials call (888) 349-3232. For additional information, contact Paul Burroughs, director of communications, (418) 652-8525, Ext. 406. Neovastat is being developed by Ęterna Laboratories of Quebec, Canada.

To learn more about anti-angiogenesis and Ęterna Laboratories, visit the Ęterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.

Google

http://www.medmeet.com/
Medical Meetings On The Net | Kids Meet | Medical Meetings | Medical Newscast | Real Time Media On The Net

Internet Meetings   medical mailings   Take It Correctly